Skip Ribbon Commands
Skip to main content
developmentpipeline

PRODUCT DEVELOPMENT

Biotie has a broad pipeline of novel, potentially first or best-in class products in clinical development

Our focus is on generating innovative, clinically differentiated medicines for the treatment of neurodegenerative and psychiatric diseases based on strong scientific, medical and commercial rationale. We aim to advance our products through Phase 2 before seeking a partnership with large pharma or biotech for late stage development and commercialization.   In situations where we believe we can be competitive, e.g. for specialty or orphan indications, we will progress our pipeline internally to registration, approval and market.  We have a dedicated team of scientists, in Europe and the US, with the drive and enthusiasm to deliver new medicines to patients.

PRODUCT PIPELINE

​Product                                                           Preclinical ​ Phase 1 ​ Phase 2​ Phase 3    ​
Regulatory/
commercial​

SelincroTM (nalmefene) - alcohol dependence
opioid antagonist​
 ü​ ü​ ü​ ü​ EU MAA filing
 submitted
(release December 21, 2011)

Tozadenant (SYN115) - Parkinson’s disease
adenosine A2a antagonist​
 ü​ ü​ Phase 2b
ongoing; data
due H1 2013​		 ​ ​

1)SYN120 - AD/cognitive disorders
5-HT6 antagonist​
 ü​ PET imaging
study; data due
H1 2012​		 ​ ​ ​

2)VAP-1 antibody – inflammatory / fibrotic disease
VAP-1 antagonist, fully human​
 ü​ ü​ Seek partner
for large
indications​		 ​ ​

Nepicastat (SYN117)
3)PTSD
4)cocaine dependence
DBH inhibitor​
 ü​ ü​
 
3)Results
expected H2 2012
 ​ ​
Ronomilast – COPD
PDE4 inhibitor​
 ü ü​ Seeking partner​ ​ ​

Nitisinone (SYN118) – Movement disorder
​		 ​ü​ ​ü​ Seeking partner​ ​ ​
 
 
1) Option agreement;
2) Asia-Pacific rights licensed to Seikagaku;
3) US Department of Defense conducting clinical study
4) US National Institute on Drug Abuse (NIDA) to fund clinical study

----------- 

Updated December 21, 2011